title: Overexpression of CD73 in prostate cancer is associated with lymph node metastasis.
abstract: Prostate cancer is the most common malignancy in men in Europe and North America. At present, it is becoming an increasingly common cancer in China. CD73 (ecto-5'-nucleotidase) is a glycosylphosphatidylinositol (GPI)-linked 70-kDa cell surface enzyme. It is also broadly expressed in many types of tissues. Recent studies have showed that CD73 is widely expressed on malignancies and is up-regulated in cancerous tissues. Consequently, we analyzed the expression of CD73 in prostate cancer tissue. The expression of the CD73 protein was evaluated by Immunohistochemistry staining in 116 tissue specimens. The expression was further examined by quantitative real-time PCR (qRT-PCR) and Western blot in the same set of patients. The intense cell membrane staining for the CD73 protein was observed. The expression of CD73 in lymph node non-metastasizing prostate cancer tissues can be seen at low levels, and is generally undetectable. RT-PCR and Western blot showed that the expression of CD73 in lymph node metastasizing prostate cancer was higher compared with non-metastasizing ones. These results suggest that CD73 could be considered as a relevant-specific target for molecular therapy of prostate cancer metastasis.
authors: Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy Tianjin, Tianjin, 300060, China, yangqingtj@163.com.
authors: Qing
authors: Q
authors: Yang
authors: Jun
authors: J
authors: Du
authors: Lingling
authors: L
authors: Zu
mesh_terms: D015720:5'-Nucleotidase / Q000096:biosynthesis* / Q000378:metabolism; D016009:Chi-Square Distribution; D058851:GPI-Linked Proteins / Q000096:biosynthesis / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*
chemical_list: D058851:GPI-Linked Proteins; D015720:5'-Nucleotidase; C548241:NT5E protein, human
references: Cancer Res. 2010 Aug 15;70(16):6407-11
references: 20682793
references: Mol Cell Biochem. 2012 Jan;359(1-2):315-22
references: 21858682
references: Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52
references: 20080644
references: J Cancer Res Clin Oncol. 2008 Mar;134(3):365-72
references: 17671792
references: Breast Cancer Res Treat. 1996;37(2):189-93
references: 8750586
references: J Clin Invest. 2011 Jun;121(6):2371-82
references: 21537079
references: Mol Cell Proteomics. 2009 Jun;8(6):1436-49
references: 19321434
references: Pharmacol Ther. 2000 Aug-Sep;87(2-3):161-73
references: 11007998
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: J Immunol. 2004 Feb 1;172(3):1646-53
references: 14734746
references: Cancer Res. 2011 Apr 15;71(8):2892-900
references: 21292811
references: J Exp Med. 1998 Oct 19;188(8):1433-43
references: 9782120
references: J Clin Invest. 1997 Jun 1;99(11):2588-601
references: 9169488
references: PLoS One. 2012;7(7):e40943
references: 22808286
references: Immunol Rev. 1998 Feb;161:95-109
references: 9553767
references: J Surg Oncol. 2012 Aug 1;106(2):130-7
references: 22287455
references: Histopathology. 2006 Apr;48(5):612-4
references: 16623792
references: J Surg Oncol. 2012 Dec;106(7):918-9; author reply 920
references: 22585744
references: Cancer Res. 2010 Mar 15;70(6):2245-55
references: 20179192
references: Eur J Immunol. 2011 May;41(5):1231-41
references: 21469131
references: Int J Cancer. 2003 Nov 20;107(4):528-34
references: 14520688
references: Purinergic Signal. 2006 Jun;2(2):351-60
references: 18404475
references: Sensors (Basel). 2012;12(5):5461-70
references: 22778595